An adverse tumor-protective effect of IDO1 inhibition

By restoring tryptophan, indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors aim to reactivate anti-tumor T cells. However, a phase III trial assessing their clinical benefit failed, prompting us to revisit the role of IDO1 in tumor cells under T cell attack. We show here that IDO1 inhibition leads to a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kenski, Juliana C.N., Huang, Xinyao, Vredevoogd, David W., de Bruijn, Beaunelle, Traets, Joleen J.H., Ibáñez-Molero, Sofía, Schieven, Sebastiaan M., van Vliet, Alex, Krijgsman, Oscar, Kuilman, Thomas, Pozniak, Joanna, Loayza-Puch, Fabricio, Terry, Alexandra M., Müller, Judith, Logtenberg, Meike E.W., de Bruijn, Marjolein, Levy, Pierre, Körner, Pierre-René, Goding, Colin R., Schumacher, Ton N., Marine, Jean-Christophe, Agami, Reuven, Peeper, Daniel S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975322/
https://www.ncbi.nlm.nih.gov/pubmed/36812891
http://dx.doi.org/10.1016/j.xcrm.2023.100941

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975322/
https://www.ncbi.nlm.nih.gov/pubmed/36812891
http://dx.doi.org/10.1016/j.xcrm.2023.100941

Ejemplares similares